Powell Andrew D, Grafton Gillian, Roberts Alexander, Larkin Shannon, O'Neill Nathanael, Palandri Josephine, Otvos Reka, Cooper Alison J, Ulens Chris, Barnes Nicholas M
Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
School of Nursing Midwifery and Social Work, Birmingham City University, Edgbaston, UK.
Br J Pharmacol. 2016 Dec;173(24):3467-3479. doi: 10.1111/bph.13638. Epub 2016 Nov 1.
The 5-HT receptor is a prototypical member of the Cys-loop ligand-gated ion channel (LGIC) superfamily and an established therapeutic target. In addition to activation via the orthosteric site, receptor function can be modulated by allosteric ligands. We have investigated the pharmacological action of Cl-indole upon the 5-HT A receptor and identified that this positive allosteric modulator possesses a novel mechanism of action for LGICs.
The impact of Cl-indole upon the 5-HT receptor was assessed using single cell electrophysiological recordings and [ H]-granisetron binding in HEK293 cells stably expressing the 5-HT receptor.
Cl-indole failed to evoke 5-HT A receptor-mediated responses (up to 30 μM) or display affinity for the [ H]-granisetron binding site. However, in the presence of Cl-indole, termination of 5-HT application revealed tail currents mediated via the 5-HT A receptor that were independent of the preceding 5-HT concentration but were antagonized by the 5-HT receptor antagonist, ondansetron. These tail currents were absent in the 5-HT AB receptor. Furthermore, the presence of 5-HT revealed a concentration-dependent increase in the affinity of Cl-indole for the orthosteric binding site of the human 5-HT A receptor.
Cl-indole acts as both an orthosteric agonist and an allosteric modulator, but the presence of an orthosteric agonist (e.g. 5-HT) is a prerequisite to reveal both actions. Precedent for ago-allosteric action is available, yet the essential additional presence of an orthosteric agonist is now reported for the first time. This widening of the pharmacological mechanisms to modulate LGICs may offer further therapeutic opportunities.
5-羟色胺受体是半胱氨酸环配体门控离子通道(LGIC)超家族的典型成员,也是一个既定的治疗靶点。除了通过正构位点激活外,受体功能还可由变构配体调节。我们研究了氯吲哚对5-羟色胺A受体的药理作用,并确定这种正变构调节剂具有一种LGICs的新作用机制。
使用单细胞电生理记录和[H] - 格拉司琼结合实验,在稳定表达5-羟色胺受体的HEK293细胞中评估氯吲哚对5-羟色胺受体的影响。
氯吲哚未能引发5-羟色胺A受体介导的反应(高达30μM),也未显示对[H] - 格拉司琼结合位点的亲和力。然而,在存在氯吲哚的情况下,5-羟色胺应用的终止显示通过5-羟色胺A受体介导的尾电流,这些尾电流与先前的5-羟色胺浓度无关,但被5-羟色胺受体拮抗剂昂丹司琼拮抗。这些尾电流在5-羟色胺AB受体中不存在。此外,5-羟色胺的存在显示氯吲哚对人5-羟色胺A受体正构结合位点的亲和力呈浓度依赖性增加。
氯吲哚既作为正构激动剂又作为变构调节剂起作用,但正构激动剂(如5-羟色胺)的存在是揭示这两种作用的先决条件。变构激动作用的先例是存在的,但正构激动剂的必要额外存在现在首次被报道。这种调节LGICs的药理机制的拓宽可能提供更多的治疗机会。